| Expert opinion  

Neuro-oncology Management During the COVID-19 Pandemic With a Focus on WHO Grade III and IV Gliomas

Neuro-oncology Management During the COVID-19 Pandemic With a Focus on WHO Grade III and IV Gliomas

 

Submitted by: Neuro-oncology Panel

Author: Bernhardt D, Wick W, Weiss SE, Sahgal A, Lo SS, Suh JH, Chang EL, Foote M, Perry J, Meyer B, Vajkoczy P, Wen PY, Straube C, Pigorsch S, Wilkens JJ, Combs SE.  

This paper by Dr Denise Bernhardt from Munich and interdisciplinary coworkers, provides and practical template for the management of malignant gliomas, where schedules for diagnostics and treatment are generally stressed by the time factor – even in “non Covid-19 times”.

They propose neurooncological treatment algorithms during SARS-CoV-19 pandemic, which can be adapted according to the needs of the individual patient, as well as according to the resources of the specific neurooncological center. Although their recommendation may be not suitable for every patient, it provides a compass towards a Covid-19 associated decision making corridor in Neurooncology, focused on grade III and grade IV gliomas, integrating supportive treatment as well as inclusion and maintenance of patients in clinical trials.

DOI: 10.1093/neuonc/noaa113. Online ahead of print. Neuro Oncol. 2020. PMID: 32369601